HALOZYME THERAPEUTICS, INC.

Halozyme Therapeutics, Inc. is a biopharmaceutical company focused on drug delivery solutions. The company developed ENHANZE drug delivery technology, which uses its proprietary enzyme, rHuPH20, to enable subcutaneous (SC) delivery of injected drugs and fluids. This technology aims to improve patient experience through rapid SC delivery and reduced treatment burden. Halozyme licenses ENHANZE to other biopharmaceutical companies to develop products combining ENHANZE with their compounds. Halozyme is also developing Hypercon drug delivery technology, an innovative microparticle technology shown in non-clinical testing to hyperconcentrate drugs and biologics, reducing injection volume for the same dosage. This could expand opportunities for at-home and healthcare provider administration. Additionally, the company is developing Surf Bio drug delivery technology to create high antibody and biologic concentrations of up to 500 mg/mL for delivery in a single auto-injector shot, for at-home or healthcare provider office use. The company also develops, manufactures, and commercializes drug-device combination products, either independently or with partners, utilizing its advanced auto-injector technologies. These products are designed to offer commercial or functional advantages like improved convenience, reliability, tolerability, enhanced patient comfort, and adherence. The ENHANZE partners' approved products and product candidates are based on rHuPH20, a patented recombinant human hyaluronidase enzyme. rHuPH20 temporarily breaks down hyaluronan, a component of the SC space, to improve and accelerate SC delivery of high-dose, high-volume injectable biologics, such as monoclonal antibodies and other large therapeutic molecules, as well as small molecules and fluids.